Skip to content

International Takotsubo Registry (InterTAK Registry)

International Multicenter Registry on Takotsubo Cardiomyopathy

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01947621
Acronym
InterTAK
Enrollment
4000
Registered
2013-09-20
Start date
2011-01-31
Completion date
2020-12-31
Last updated
2014-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Takotsubo Cardiomyopathy

Keywords

Broken heart syndrome, stress cardiomyopathy

Brief summary

This is a multicenter, multinational, prospective and retrospective, observational study of patients with Takotsubo cardiomyopathy (TTC). Data on natural profile (demographical characteristics, clinical phenotype, laboratory values, electrocardiography parameters, echocardiography parameters, coronary angiography parameters, medication) and outcome are systematically collected. Our aim is to gain a better insight into the clinical profile and pathophysiology of TTC.

Detailed description

Registry is an open-ended study and eligible individuals are assessed at index event and follow-up on their phenotypical characteristics. Furthermore, outcome data are collected (by clinical visits or telephone follow-up). In addition, participants are given the option to consent to the donation of biosamples for the purposes to identify TTC specific biomarkers and mutations (sub-study on behalf of the registry).

Interventions

None listed

Sponsors

University of California, Davis
CollaboratorOTHER
Hannover Medical School
CollaboratorOTHER
Ludwig-Maximilians - University of Munich
CollaboratorOTHER
University of Heidelberg Medical Center
CollaboratorOTHER
University Hospital Schleswig-Holstein
CollaboratorOTHER
Charite University, Berlin, Germany
CollaboratorOTHER
University of Kentucky
CollaboratorOTHER
Medical University of Cologne
CollaboratorOTHER
University Hospital, Saarland
CollaboratorOTHER
University Hospital, Essen
CollaboratorOTHER
Asklepios Kliniken Hamburg GmbH
CollaboratorOTHER
University Hospital Goettingen
CollaboratorOTHER
University of Magdeburg
CollaboratorOTHER
Oxford University Hospitals NHS Trust
CollaboratorOTHER
Kantonsspital Winterthur KSW
CollaboratorOTHER
Turku University Hospital
CollaboratorOTHER_GOV
Medical University of Gdansk
CollaboratorOTHER
Medical University of Warsaw
CollaboratorOTHER
University Hospital, Basel, Switzerland
CollaboratorOTHER
Catholic University of the Sacred Heart
CollaboratorOTHER
Medical University Innsbruck
CollaboratorOTHER
Cardiocentro Ticino
CollaboratorOTHER
Luzerner Kantonsspital
CollaboratorOTHER
Mayo Clinic
CollaboratorOTHER
University of Zurich
Lead SponsorOTHER

Study design

Observational model
COHORT

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Mayo Clinic Diagnostic Criteria (Prasad et al. American Heart Journal 2008) 1. Transient hypokinesis, akinesis, or dyskinesis of the left ventricular mid segments with or without apical involvement; the regional wall motion abnormalities extend beyond a single epicardial vascular distribution; a stressful trigger is often, but not always present.\* 2. Absence of obstructive coronary disease or angiographic evidence of acute plaque rupture. † 3. New electrocardiographic abnormalities (either ST-segment elevation and/or T-wave inversion) or modest elevation in cardiac troponin. In both of the above circumstances, the diagnosis of TTC should be made with caution, and a clear stressful precipitating trigger must be sought. \* There are rare exceptions to these criteria such as those patients in whom the regional wall motion abnormality is limited to a single coronary territory. † It is possible that a patient with obstructive coronary atherosclerosis may also develop TTC.

Exclusion criteria

Patients with Myocarditis

Design outcomes

Primary

MeasureTime frameDescription
Natural history of TTC10 yearsTo determine the natural history of Takotsubo cardiomyopathy.

Secondary

MeasureTime frameDescription
Cardiovascular complications, recurrence of TTC and all cause mortalityat hospitalizsation, short term (1 year) and long term (10 years)Patients will be assessed for cardiovascular complications during hospitalisation and at follow-up (up to 10 years)

Countries

Switzerland

Contacts

Primary ContactChristian Templin, MD, PhD
christian.templin@usz.ch+41 44 255 95 85

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 2, 2026